LSL Pharma Group Announces an Extension of its Convertible Debentures Offering
January 08 2024 - 7:00AM
LSL Pharma Group Inc. (TSXV: LSL) – (the “
Company”
or “
LSL Pharma Group”), a Canadian integrated
pharmaceutical company, announces that it extends until February 7,
2024 its brokered private placement through the issuance of
unsecured convertible debentures at a price of $10 per debenture
(the “
Offering”). As announced on December 8,
2023, LSL Pharma Group has now raised total gross proceeds of
$3,288,000 under the Offering out of a maximum of $5,000,000
(assuming the full exercise of the agent's option to increase the
size of the Offering by up to $1.0 million). The net proceeds of
the Offering will be used for working capital, capital
expenditures, and for general corporate purposes.
Disclaimers
The securities issued in connection with the
Offering mentioned herein have not been and will not be qualified
for sale to the public under applicable Canadian securities laws
and, accordingly, any offer and sale of securities in Canada will
be made on a basis which is exempt from the prospectus and, when
applicable, dealer registration requirements of such securities
laws. Furthermore, none of the securities issued in connection with
the Offering will be registered under the United States Securities
Act of 1933, as amended (the "1933 Act") or of any
other jurisdiction, and none of them may be offered or sold in the
United States or in any other jurisdiction absent registration or
an applicable exemption from the registration requirements of the
1933 Act or of any other jurisdiction. This press release shall not
constitute an offer to sell or a solicitation of an offer to buy
nor shall there be any sale of any of the securities in any
jurisdiction in which such an offer, solicitation, or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction.
Forward-Looking Statements
Information provided and statements contained in
this press release that are not purely historical, such as those on
the revenue and the EBITDA, are forward-looking statements within
the meaning of the applicable securities laws. Certain statements
in this press release may constitute forward-looking information
within the meaning of securities laws. Forward-looking information
may relate to LSL Pharma Group’s future outlook and anticipated
events, business, operations, financial performance, financial
condition or results and, in some cases, can be identified by
terminology such as “may”; “will”; “should”; “expect”; “plan”;
“anticipate”; “believe”; “intend”; “estimate”; “predict”;
“potential”; “continue”; “foresee”, “ensure” or other similar
expressions concerning matters that are not historical facts. The
reader should not place undue importance on forward-looking
information and should not rely upon this information as of any
other date. LSL Pharma Group will not update these statements
unless applicable securities laws require LSL Pharma Group to do
so.
ABOUT LSL PHARMA GROUP
INC.
LSL Pharma Group is a Canadian integrated
pharmaceutical company specializing in the development,
manufacturing and distribution of high-quality natural health
products and dietary supplements in solid dosage forms, as well as
high quality sterile ophthalmic pharmaceutical products. For more
information, please visit www.groupelslpharma.com.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
CONTACT:François Roberge,
President and Chief Executive Officer Telephone:
514-664-7700Email: Investors@groupelslpharma.com
LSL Pharma (TSXV:LSL)
Historical Stock Chart
From May 2024 to Jun 2024
LSL Pharma (TSXV:LSL)
Historical Stock Chart
From Jun 2023 to Jun 2024